A Meeting of the Board of Directors of Sandu Pharmaceuticals Limited was duly convened on Tuesday, 11th August 2026 at 04:00 p.m. and concluded at 5:15 p.m.

1. Financial Results

The Board approved the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2026, along with the Limited Review Report issued by the Statutory Auditors, M/s. Dileep & Prithvi Chartered Accountants (Firm Registration Number: 122329). The review report expressed an unmodified conclusion, stating that based on their review, nothing has come to their attention that causes them to believe that the financial results contain any material misstatement.

The financial results show:

  • Profit/(loss) before tax: ₹36.05 lakh (current quarter), ₹74.71 lakh (corresponding quarter of previous year), ₹33.87 lakh (preceding quarter)
  • Tax expense: Current tax ₹-5.37 lakh, Deferred tax ₹3.86 lakh, Short/Excess tax provision ₹0.00
  • Profit for the period: ₹2.8 lakh
  • Other Comprehensive Income: ₹15.52 lakh
  • Total Comprehensive Income for the period: ₹38.35 lakh
  • Earnings per equity share (Basic & Diluted): ₹0.37
  • Paid-up equity share capital: ₹966.10 lakh

The management evaluates performance based on one segment: "Ayurvedic Proprietary Medicines." The figures for the quarter ended 30th June, 2026 are balancing figures between the audited full financial year and published year-to-date figures.

2. Annual Report Components

The Board approved the Directors' Report, Management Discussion and Analysis Report, Corporate Governance Report, Secretarial Audit Report and other reports forming part of the Annual Report for FY 2025-26.

3. Record Date

The Board approved the closure of the Register of Members and Share Transfer Books from Friday, September 4, 2026 to Friday, September 11, 2026 (both days inclusive) for the ensuing Annual General Meeting. The Record Date for determining eligibility of Members entitled to receive the proposed dividend for FY ended March 31, 2026 is Friday, September 4, 2026.

4. Fund Utilization Statement

The Board took note of the Statement of Utilisation and Statement of Deviation(s) in utilisation of funds, if any, as required under Regulation 32 of SEBI LODR for the quarter ended June 30, 2026.

5. Annual General Meeting

The Board approved convening the 41st Annual General Meeting on Friday, September 11, 2026, at 4:30 P.M. (IST) through Video Conferencing/Other Audio-Visual Means.

6. Material Related Party Transactions

The Board recommended obtaining member approval at the AGM for continuation of Material Related Party Transactions with M/s. Sandu Brothers Private Limited.

7. Appointment of Statutory Auditors

Based on the recommendation of the Audit Committee, the Board approved and recommended the appointment of M/s. Dave & Dave, Chartered Accountants (Firm Registration No. 102163W) as Statutory Auditors for a first term of five consecutive years, commencing from the conclusion of the ensuing AGM until the conclusion of the AGM in 2031.

M/s. Dave & Dave is a partnership firm established in 1989 based in Mumbai with 2 partners, 2 associates and 10 staff members. The firm holds Peer Review Certificate No. 020259 valid from 25 March 2025 to 31 March 2028. The firm has extensive experience in statutory, internal, management, stock and tax audits, along with corporate law and secretarial compliances. The firm is not related to any Directors, Key Managerial Personnel, or Promoters of the Company.